Phaseline

Targets › TFR2

TFR2 (Transferrin receptor protein 2): drug programs, companies and trials

1 program from 1 company in 3 trials: 2 Phase 2, 1 Phase 3; Metabolic and endocrine; next expected readout Dec 2026.

Mediates cellular uptake of transferrin-bound iron in a non-iron dependent manner. May be involved in iron metabolism, hepatocyte function and erythrocyte differentiation. (UniProt, Q9UP52)

Open in Phaseline: the race on TFR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
JCR PharmaceuticalsPabinafusp Alfa (JR-141)
Transferrin receptor binding agent
TFRC, TFR2Phase 3Mucopolysaccharidosis IIDec 2026

Conditions

Mucopolysaccharidosis II (3)

Modalities

small molecule (1)

Companies

JCR Pharmaceuticals (1)

Related targets

TFRC (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.